CytoDyn Inc. Files S-1 with SEC

TL;DR

CytoDyn filed an S-1, check financials and future plans.

AI Summary

CytoDyn Inc. filed an S-1 form on September 9, 2024, detailing its financial status and business operations. The company, previously known as Rexray Corp, is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its fiscal year ends on May 31, and its principal executive offices are located in Vancouver, Washington.

Why It Matters

This S-1 filing provides crucial information for investors and the public regarding CytoDyn Inc.'s financial health, business strategy, and any potential securities offerings.

Risk Assessment

Risk Level: medium — S-1 filings often precede significant corporate actions like stock offerings, which can introduce volatility and risk for existing shareholders.

Key Numbers

• 0531 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
• 360-980-8524 — Business Phone (Contact number for CytoDyn Inc.)

Key Players & Entities

• CytoDyn Inc. (company) — Filer of the S-1 document
• Rexray Corp (company) — Former name of CytoDyn Inc.
• September 9, 2024 (date) — Filing date of the S-1
• Vancouver, Washington (location) — Location of CytoDyn Inc.'s business address
• 333-282000 (dollar_amount) — SEC file number for CytoDyn Inc.

FAQ

Key Financial Figures

• $0.001 — 9 shares of our common stock, par value $0.001 per share (the "common stock"), and 207
• $0.16 — e closing price of our common stock was $0.16 per share. Investing in our securities
• $0.10 — and December 2022, an exercise price of $0.10 per share and an additional two warrant
• $0.50 — common stock with an exercise price of $0.50 per share, for total proceeds of approx
• $16.5 million — re, for total proceeds of approximately $16.5 million (the "March 2023 Placement"). The warra
• $0.1 million — re, for total proceeds of approximately $0.1 million. The terms and conditions of the sale a
• $0.23 — The warrants have an exercise price of $0.23 per share, and include a cashless exerc
• $0.37 — common stock with an exercise price of $0.37 per share in connection with the settle
• $3.4 million — re, for total proceeds of approximately $3.4 million. The warrants issued to investors have
• $2.3 million — egate principal amount of approximately $2.3 million ("Placement Agent Notes"). The Placemen
• $0.26 — The warrants have an exercise price of $0.26 per share and include a cashless exerci
• $0.306 — common stock with an exercise price of $0.306 per share. The warrants issued in these
• $3.3 million — re, for total proceeds of approximately $3.3 million. The warrants issued in these transacti
• $1.00 — common stock with an exercise price of $1.00 per share, for total proceeds of approx
• $11.4 million — re, for total proceeds of approximately $11.4 million. The warrants issued in these transacti

Filing Documents

• cydy-20240531xs1.htm (S-1) — 4135KB
• cydy-20240531xex5d1.htm (EX-5.1) — 11KB
• cydy-20240531xex23d1.htm (EX-23.1) — 3KB
• cydy-20240531xex23d2.htm (EX-23.2) — 3KB
• cydy-20240531xexfees.htm (EX-FILING FEES) — 90KB
• cydy-20240531xs1008.jpg (GRAPHIC) — 9KB
• cydy-20240531xex5d1001.jpg (GRAPHIC) — 9KB
• cydy-20240531xex5d1002.jpg (GRAPHIC) — 6KB
• cydy-20240531xex5d1003.jpg (GRAPHIC) — 7KB
• cydy-20240531xex5d1004.jpg (GRAPHIC) — 2KB
• 0001558370-24-012660.txt ( ) — 12635KB
• cydy-20240531.xsd (EX-101.SCH) — 89KB
• cydy-20240531_cal.xml (EX-101.CAL) — 64KB
• cydy-20240531_def.xml (EX-101.DEF) — 334KB
• cydy-20240531_lab.xml (EX-101.LAB) — 568KB
• cydy-20240531_pre.xml (EX-101.PRE) — 557KB
• cydy-20240531xs1_htm.xml (XML) — 1851KB

USE OF PROCEEDS

USE OF PROCEEDS 22 MARKET FOR OUR COMMON STOCK AND DIVIDEND POLICY 23 OUR BUSINESS 24

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 43 MANAGEMENT 50 EXECUTIVE AND DIRECTOR COMPENSATION 53 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 59

SECURITY OWNERSHIP BY CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP BY CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 61 SELLING STOCKHOLDERS 62 PLAN OF DISTRIBUTION 75

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 77 SECURITIES ACT RESTRICTIONS ON RESALE OF SECURITIES 81 LEGAL MATTERS 82 EXPERTS 82 WHERE YOU CAN FIND MORE INFORMATION 82 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 In making your investment decision, you should rely only on the information contained in this prospectus. We have not authorized anyone to provide you with different or additional information. We are not making an offer to sell or seeking an offer to buy any shares of common stock in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is complete and accurate as of any date other than the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of securities offered hereby. Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 (the "Registration Statement") that we filed with the SEC. You should read this prospectus and the exhibits filed with or incorporated by reference in the Registration Statement carefully. Such documents contain important information you should consider when making your investment decision. See "Where You Can Find More Information" in this prospectus. This prospectus may be supplemented from time to time to add, update, or change information in this prospectus. Any statement contained in this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in such prospectus supplement modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. You may only rely on the information contained in this prospectus or that we have referred you to. We have not authorized anyone to provide you with different information. This prospectus

View Full Filing

View this S-1 filing on SEC EDGAR